A PROSPECTIVE MULTICENTRIC, PROOF OF CONCEPT STUDY TO EVALUATE THE VALUE OF 18-FDG-PET-SCAN ON TUMOUR RESPONSE IN PATIENTS WITH A PROGRESSIVE PANCREATIC ENDOCRINE TUMOUR RECEIVING A COMBINATION THERAPY OF LANREOTIDE AUTOGEL 120 MG EVERY 28 DAYS AND SUNITINIB 37.5 MG DAILY

Trial Profile

A PROSPECTIVE MULTICENTRIC, PROOF OF CONCEPT STUDY TO EVALUATE THE VALUE OF 18-FDG-PET-SCAN ON TUMOUR RESPONSE IN PATIENTS WITH A PROGRESSIVE PANCREATIC ENDOCRINE TUMOUR RECEIVING A COMBINATION THERAPY OF LANREOTIDE AUTOGEL 120 MG EVERY 28 DAYS AND SUNITINIB 37.5 MG DAILY

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Feb 2017

At a glance

  • Drugs Fludeoxyglucose F-18 (Primary) ; Lanreotide (Primary) ; Sunitinib (Primary)
  • Indications Neuroendocrine tumours; Pancreatic cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SULA-P Study
  • Most Recent Events

    • 16 Feb 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top